Article
Benefits of NGS in Advanced Lung Adenocarcinoma Vary by Populations and Timing of Examination.
International journal of molecular sciences - 25 Jun 2024
Lee Po-Hsin, Ou Wei-Fan, Huang Yen-Hsiang, Hsu Kuo-Hsuan, Tseng Jeng-Sen, Chang Gee-Chen, Yang Tsung-Ying
Abstract excerpt
Despite the widespread application of next-generation sequencing (NGS) in advanced lung adenocarcinoma, its impact on survival and the optimal timing for the examination remain uncertain. This cohort study included advanced lung adenocarcinoma patients who underwent NGS testing. We categorized patients into four groups: Group 1: treatment-naïve, upfront NGS; Group 2: Treatment-naïve, exclusionary EGFR/ALK/ROS1;...
Topics
Join the communities discussing this publication.
